Bergs Securities is proud to have acted as sole global coordinator & joint bookrunner to NanoEcho in its SEK 17 million rights issue
NanoEcho is a Swedish life science company developing a new diagnostic method to determine whether early rectal cancer has spread to nearby lymph nodes – a method that has the potential to generate significant health economic gains. NanoEcho’s imaging device is fully developed and meets the requirements of both customers and regulatory authorities for medical devices. The system is now being evaluated in a clinical study. NanoEcho’s strategy includes NanoEcho introducing a new method for improved diagnostics of early rectal cancer and applying for authority approval for its imaging system during 2027.
